New structure and logo for European Medicines Agency
• By Maureen Kenny
The European Medicines Agency today officially launched its new organisational structure along with a new visual identity1-4. The highlights of the new structure, which was announced in October5,6, include the integration of human pre- and post-authorisation activities into one unit “to guarantee seamless lifecycle-management of medicines”. There is also a new unit for patient health protection, which, according to the EMA (formerly the EMEA7,8), further strengthens its focus on safety-monitoring of medicines. A dedicated group has been set up to deal with the management of product data and documentation in a move that is aimed at improving the efficiency of data management processes throughout the agency. This is the second major reorganisation of the agency’s services since the body was established in 1995. Logo The new logo is a stylised representation of a mortar and pestle. This, according to the EMA, is “one of the most ancient and universally recognised images associated with medicines, which are the core focus of the Agency”. Figure 1. New EMA logo The logo incorporates the words science, medicines and health, which “represent the three pillars on which all of [the agency’s] work is based”. A new EMA website is expected to be launched early in 2010. References 1. EMA press release, EMA/704918/2009, 8 December 2009, www.emea.europa.eu/pdfs/general/direct/pr/70491809en.pdf 2. EMA information document, EMA/704918/2009, 8 December 2009, www.emea.europa.eu/htms/general/direct/visual_identity.htm 3. EMA organisational structure, www.emea.europa.eu/pdfs/general/direct/organisation.pdf 4. Guide to the European Medicines Agency, EMA/765521/2009, 8 December 2009, www.emea.europa.eu/pdfs/general/direct/76552109en.pdf 5. EMEA press release, 5 October 2009, www.emea.europa.eu/pdfs/general/direct/pr/52017309en.pdf 6. RAJ Pharma online, 6 October 2009 7. EMEA document, EMEA/747665/2009, 30 November 2009, www.emea.europa.eu/pdfs/general/direct/74766509en.pdf 8. RAJ Pharma online, 30 November 2009
The European Medicines Agency today officially launched its new organisational structure along with a new visual identity1-4.
The highlights of the new structure, which was announced in October5,6, include the integration of human pre- and post-authorisation activities into one unit “to guarantee seamless lifecycle-management of medicines”. There is also a new unit for patient health protection, which, according to the EMA (formerly the EMEA7,8), further strengthens its focus on safety-monitoring of medicines
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Decision in AstraZeneca’s lawsuit against the Health and Human Services Department is a precedent-setting victory for the government and a blow to manufacturer efforts to block the price negotiation program.
Advisory committee for Capricor’s deriamocel planned, regenerative medicine advanced therapy designations proliferate for osteoarthritis, and the ranks of dual RMAT/breakthrough therapy designation holders grow.
